INTRODUCTION 22
Aerococcus urinae is a Gram-positive coccus with the capacity to cause 23 urinary tract infections (7), infectious endocarditis (IE) (6), and spondylodiscitis (3). 24
A. urinae was recognized as a distinct species in 1992 (1) and can be misreported as 25 an α-hemolytic streptococcus due to its growth characteristics and hemolysis pattern. 26
Correct classification is based on sequencing of the 16S rRNA gene. The bacterium is 27 generally susceptible to penicillin, vancomycin, and cephalosporins whereas it is 28 resistant to sulfonamide (8, 28) . Patients who present with severe infection are 29 typically elderly men with underlying urinary tract abnormalities. Twenty cases of A. 30 urinae IE have been described in the literature and the case fatality is around 50 % 31 (10, 15). Despite reports of invasive disease caused by A. urinae, including IE, 32
nothing is known about potential virulence strategies of the bacterium. 33
Biofilm formation is believed to contribute to the ability of a bacterium to 34 colonize foreign materials such as urinary tract catheters. In the biofilm, the bacteria 35 are protected against host defenses and against antibiotics. The first step in the 36 pathogenesis of IE is believed to be bacterial adherence to damaged heart valves. This 37 is followed by bacterial accumulation and probably also formation of a bacterial 38 biofilm (9). In addition, fibrin, neutrophils, and platelets are deposited on the infected 39 heart valve leading to the formation of a typical IE vegetation. 40
The majority of Gram-positive pathogens that cause IE interact with and 41 activate human platelets and this has been proposed to contribute to virulence. The 42 molecular mechanisms leading to platelet activation have been described in detail for 43 many pathogens (recently reviewed in (11, 16)). Many pathogens activate platelets 44 through bacterial bound fibrinogen in combination with specific immunoglobulin G 45 (IgG) bound to the bacterial surface. This mechanism has been described for 46 IdeS was purified as a fusion to GST as previously described (30). For some 113 experiments, 0.1 mg of trypsin from bovine pancreas (Sigma) was added to 100 µl of 114 bacterial suspension (2.6x10 9 /ml in PBS) followed by incubation at 37 o C for 30 115 minutes. Trypsin was blocked by the addition of benzamidine hydrochloride (Sigma) 116 to a final concentration of 6 mM. After incubation for 5 minutes the sample was 117 centrifuged at 3000g for 5 minutes and the bacterial pellet was resuspended in 100 µl 118 of PBS. For some experiments, PGE 1 was added to a final concentration of 1 µM to 119 PRP and incubated for 5 minutes before addition of agonist. Serum was prepared 120 from blood that was allowed to coagulate in glass tubes for one hour followed by 121 centrifugation at 1500g for 10 minutes. for all isolates at 72 hours is illustrated in figure 1A . The addition of 10 % human 178 plasma to the growth medium lead to an increased amount of dye bound to the biofilm 179 of all isolates by 30-758 % (mean 397 %). To investigate if the stimulatory effect of 180 plasma was due to increased adherence of bacteria to the surface, the wells were 181 pretreated with 20 % plasma in TSBG for 2 hours followed by removal of plasma and 182 determination of biofilm formation. Pretreatment of wells did not increase biofilm 183 on October 2, 2017 by guest http://iai.asm.org/ Downloaded from formation but rather decreased the biofilm formation of the five isolates with 47-66 % 184 (Fig. 1) . This indicates that the stimulatory effect of plasma on biofilm formation is 185 not explained by the presence of plasma proteins at the plastic surface. The biofilms 186 formed by two isolates (Au1 and Au3) on glass cover slips in the presence or absence 187 of 10 % human plasma were visualized by scanning electron microscopy (SEM, Fig.  188 2). Both isolates formed multilayered bacterial conglomerates on the glass surface. An 189 intercellular substance covers the bacterial aggregates present in the biofilm formed 190 by Au1 irrespective of the presence of plasma ( Fig. 2A and 2B ). In the biofilm formed 191 by Au3 intercellular substance could be seen only on bacteria grown in the presence 192 of plasma ( Fig. 2C and 2D ). This likely reflects the ability of Au1 to produce biofilm 193 in the microtiter plates irrespective of the plasma content, while formation of biofilm 194 by Au3 in the microtiter plates was stimulated by plasma (Fig 1) . (Table 1) . One isolate, Au3, induced aggregation in all donors, whereas one 203 isolate (Au4) failed to induce aggregation in any donor (Table 1) system. Some mechanisms described for platelet aggregation with a long lag-time to 228 aggregation involve activation of the complement system. To determine if this was 229 the case for A. urinae, Au3 bacteria were pretreated with 100 µl of PPP for 15 230 minutes followed by addition of 400 µl of PRP from donor 1 (Fig 4A) . As a control 231 Au3 bacteria were added to a mixture of 100 µl of PPP and 400 µl of PRP from the 232 same donor. As can be seen in figure 4A , pretreatment of bacteria with plasma 233 on October 2, 2017 by guest http://iai.asm.org/ Downloaded from shortens the lag-time to aggregation significantly, suggesting that Au3 accumulates 234 components, which participate in platelet aggregation. 235
Next, 100 µl of washed platelets was added to 350 µl of plasma or serum followed by 236 the addition of Au3 bacteria (Fig 4B) . As expected, platelets aggregated in plasma but 237 not in serum, which contains only small amounts of fibrinogen. When fibrinogen was 238 added to serum, Au3 was able to induce aggregation of platelets (Fig 4B) . In contrast, 239 in serum pretreated at 56 o C with added fibrinogen, Au3 was unable to induce platelet 240 aggregation indicating a role for the complement system in platelet aggregation. 241
Importantly, the AP1 strain of S. pyogenes could aggregate washed platelets 242 suspended in heat-treated serum with added fibrinogen (Fig 4B) . In similar 243 experiments, zymosan was used to deplete serum of complement proteins (14). When 244 washed platelets were added to zymosan-depleted serum reconstituted with fibrinogen 245 aggregation by Au3 still occurred. However, the lag-time to aggregation was 246 increased (38, 41, and 78 % in three separate experiments) as compared to the lag-247 time in normal serum reconstituted with fibrinogen (data not shown). no longer bind to the platelets (Fig 5B) , but platelet activation in response to ADP still 260 occurred and as demonstrated by CD62 presentation (Fig 5B) . When the fibrinogen 261 receptor was blocked, activation of platelets by Au3 was significantly decreased in all 262 donors (Fig 5A and 5B) . This indicates that the fibrinogen receptor at the platelet 263 surface is involved in platelet activation by Au3. 264
We next tested the ability of the A. urinae isolates to bind radiolabeled 265 fibrinogen. The AP1 strain of S. pyogenes, which binds fibrinogen with high affinity 266 via the M1 protein (2), was used as a positive control. The ability of 10 9 bacteria/ml to 267 bind fibrinogen is shown in figure 5C . Au3 absorbed a higher proportion of added 268 fibrinogen as compared to the other isolates. Competitive binding studies were carried 269 out where unlabelled fibrinogen was allowed to compete with radiolabeled fibrinogen 270 for binding to 10 8 Au3 bacteria or to 2x10 7 AP1 bacteria (Fig. 5D) . In both isolates, 271 the unlabelled fibrinogen could compete with the labeled fibrinogen for binding 272 indicating that binding was specific. 273 274 A. urinae platelet aggregation is dependent on IgG. To determine the role 275 of plasma IgG in mediating platelet activation, the platelet receptor for the Fc part of 276
IgG was blocked using a monoclonal antibody (AT10). As expected, platelet 277 activation in response to ADP was unaffected by blockade of the platelet IgG receptor 278 but AT10 diminished activation in response to Au3 in all donors (Fig. 6A and 6B) . cause platelet aggregation and the addition of serum from the same donor did not 294 stimulate platelet aggregation (Fig 6D) . As expected, Au3 induced aggregation of 295 platelets in PRP from donor 1 also after the addition of control serum. Importantly, 296 the addition of patient serum induced platelet aggregation in PRP from donor 1 in 297 response to Au1 (Fig. 6D) In this work we demonstrate that A. urinae can form biofilms and that the 304 bacteria can aggregate human platelets. It is the first report of potential virulence 305 mechanisms for this pathogen and both mechanisms may contribute to the ability of 306
A. urinae to cause IE. A. urinae is well documented as a pathogen in IE though the 307 number of reported cases is low (10, 15). We identified three cases of IE and two 308 additional cases of invasive infection with A. urinae during a four year period in a 309 population of around 400 000 inhabitants. This indicates that the importance of A. 310 urinae as a pathogen in IE and other invasive diseases has previously been 311 underestimated. In accordance with previous reports, the patients in this study were 312 all older males and though the material is too small to draw any definite conclusions, 313
A. urinae may be a significant cause of IE among older men. Au3 and platelet GPIIb/IIIa is involved in platelet activation by this isolate. 345
Complement activation may also be important for the ability of the other A. urinae 346 isolates to induce platelet aggregation since a long lag-time was observed for all 347
isolates. In addition to these host proteins, a bacterial protein structure seems to be 348 
